vs
Artisan Partners Asset Management Inc.（APAM）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
Artisan Partners Asset Management Inc.的季度营收约是Bio-Techne的1.1倍（$335.5M vs $311.4M），Artisan Partners Asset Management Inc.净利率更高（35.2% vs 16.4%，领先18.8%），Artisan Partners Asset Management Inc.同比增速更快（12.9% vs -1.5%），过去两年Artisan Partners Asset Management Inc.的营收复合增速更高（12.7% vs 1.3%）
阿蒂森伙伴资产管理公司（Artisan Partners）是总部位于美国威斯康星州密尔沃基的资产管理机构，除美国本土外，还在都柏林、香港、伦敦、新加坡、悉尼设有办公室，为全球客户提供专业的资产管理服务。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
APAM vs TECH — 直观对比
营收规模更大
APAM
是对方的1.1倍
$311.4M
营收增速更快
APAM
高出14.5%
-1.5%
净利率更高
APAM
高出18.8%
16.4%
两年增速更快
APAM
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $335.5M | $311.4M |
| 净利润 | $118.1M | $51.0M |
| 毛利率 | — | 66.9% |
| 营业利润率 | 39.2% | 24.2% |
| 净利率 | 35.2% | 16.4% |
| 营收同比 | 12.9% | -1.5% |
| 净利润同比 | 34.9% | 126.0% |
| 每股收益（稀释后） | $1.36 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APAMTECH
| Q1 26 | — | $311.4M | ||
| Q4 25 | $335.5M | $295.9M | ||
| Q3 25 | $301.3M | — | ||
| Q2 25 | $282.7M | $317.0M | ||
| Q1 25 | $277.1M | $316.2M | ||
| Q4 24 | $297.1M | $297.0M | ||
| Q3 24 | $279.6M | $289.5M | ||
| Q2 24 | $270.8M | $306.1M |
净利润APAMTECH
| Q1 26 | — | $51.0M | ||
| Q4 25 | $118.1M | $38.0M | ||
| Q3 25 | $66.8M | — | ||
| Q2 25 | $67.6M | $-17.7M | ||
| Q1 25 | $61.1M | $22.6M | ||
| Q4 24 | $87.5M | $34.9M | ||
| Q3 24 | $73.0M | $33.6M | ||
| Q2 24 | $57.6M | $40.6M |
毛利率APAMTECH
| Q1 26 | — | 66.9% | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
营业利润率APAMTECH
| Q1 26 | — | 24.2% | ||
| Q4 25 | 39.2% | 18.4% | ||
| Q3 25 | 33.8% | — | ||
| Q2 25 | 28.2% | -7.5% | ||
| Q1 25 | 31.2% | 12.2% | ||
| Q4 24 | 36.7% | 16.0% | ||
| Q3 24 | 33.3% | 13.8% | ||
| Q2 24 | 32.0% | 15.0% |
净利率APAMTECH
| Q1 26 | — | 16.4% | ||
| Q4 25 | 35.2% | 12.8% | ||
| Q3 25 | 22.2% | — | ||
| Q2 25 | 23.9% | -5.6% | ||
| Q1 25 | 22.1% | 7.1% | ||
| Q4 24 | 29.5% | 11.7% | ||
| Q3 24 | 26.1% | 11.6% | ||
| Q2 24 | 21.3% | 13.3% |
每股收益（稀释后）APAMTECH
| Q1 26 | — | $0.32 | ||
| Q4 25 | $1.36 | $0.24 | ||
| Q3 25 | $0.93 | — | ||
| Q2 25 | $0.94 | $-0.11 | ||
| Q1 25 | $0.82 | $0.14 | ||
| Q4 24 | $0.99 | $0.22 | ||
| Q3 24 | $1.03 | $0.21 | ||
| Q2 24 | $0.80 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $209.8M |
| 总债务越低越好 | $190.0M | — |
| 股东权益账面价值 | $438.8M | $2.1B |
| 总资产 | $1.6B | $2.6B |
| 负债/权益比越低杠杆越低 | 0.43× | — |
8季度趋势，按日历期对齐
现金及短期投资APAMTECH
| Q1 26 | — | $209.8M | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M |
总债务APAMTECH
| Q1 26 | — | — | ||
| Q4 25 | $190.0M | $260.0M | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $200.0M | $346.0M | ||
| Q1 25 | $200.0M | $330.0M | ||
| Q4 24 | $200.0M | $300.0M | ||
| Q3 24 | $200.0M | $300.0M | ||
| Q2 24 | $200.0M | $319.0M |
股东权益APAMTECH
| Q1 26 | — | $2.1B | ||
| Q4 25 | $438.8M | $2.0B | ||
| Q3 25 | $402.1M | — | ||
| Q2 25 | $381.8M | $1.9B | ||
| Q1 25 | $356.5M | $2.0B | ||
| Q4 24 | $388.9M | $2.1B | ||
| Q3 24 | $372.1M | $2.1B | ||
| Q2 24 | $341.2M | $2.1B |
总资产APAMTECH
| Q1 26 | — | $2.6B | ||
| Q4 25 | $1.6B | $2.5B | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.4B | $2.6B | ||
| Q1 25 | $1.4B | $2.6B | ||
| Q4 24 | $1.6B | $2.7B | ||
| Q3 24 | $1.6B | $2.7B | ||
| Q2 24 | $1.5B | $2.7B |
负债/权益比APAMTECH
| Q1 26 | — | — | ||
| Q4 25 | 0.43× | 0.13× | ||
| Q3 25 | 0.47× | — | ||
| Q2 25 | 0.52× | 0.18× | ||
| Q1 25 | 0.56× | 0.16× | ||
| Q4 24 | 0.51× | 0.14× | ||
| Q3 24 | 0.54× | 0.14× | ||
| Q2 24 | 0.59× | 0.15× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $172.0M | — |
| 自由现金流经营现金流 - 资本支出 | $171.6M | — |
| 自由现金流率自由现金流/营收 | 51.2% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | 1.46× | — |
| 过去12个月自由现金流最近4个季度 | $420.6M | — |
8季度趋势，按日历期对齐
经营现金流APAMTECH
| Q1 26 | — | — | ||
| Q4 25 | $172.0M | — | ||
| Q3 25 | $40.4M | — | ||
| Q2 25 | $50.9M | $98.2M | ||
| Q1 25 | $157.9M | $41.1M | ||
| Q4 24 | $372.8M | $84.3M | ||
| Q3 24 | $112.8M | $63.9M | ||
| Q2 24 | $75.9M | $75.5M |
自由现金流APAMTECH
| Q1 26 | — | — | ||
| Q4 25 | $171.6M | — | ||
| Q3 25 | $40.4M | — | ||
| Q2 25 | $50.9M | $93.3M | ||
| Q1 25 | $157.7M | $31.0M | ||
| Q4 24 | $371.3M | $77.5M | ||
| Q3 24 | $112.4M | $54.7M | ||
| Q2 24 | $75.2M | $57.5M |
自由现金流率APAMTECH
| Q1 26 | — | — | ||
| Q4 25 | 51.2% | — | ||
| Q3 25 | 13.4% | — | ||
| Q2 25 | 18.0% | 29.4% | ||
| Q1 25 | 56.9% | 9.8% | ||
| Q4 24 | 125.0% | 26.1% | ||
| Q3 24 | 40.2% | 18.9% | ||
| Q2 24 | 27.8% | 18.8% |
资本支出强度APAMTECH
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.1% | 3.2% | ||
| Q4 24 | 0.5% | 2.3% | ||
| Q3 24 | 0.1% | 3.2% | ||
| Q2 24 | 0.2% | 5.9% |
现金转化率APAMTECH
| Q1 26 | — | — | ||
| Q4 25 | 1.46× | — | ||
| Q3 25 | 0.60× | — | ||
| Q2 25 | 0.75× | — | ||
| Q1 25 | 2.58× | 1.82× | ||
| Q4 24 | 4.26× | 2.42× | ||
| Q3 24 | 1.54× | 1.90× | ||
| Q2 24 | 1.32× | 1.86× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APAM
暂无分部数据
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
